Axplora Announces €6.5 Million Investment at Vizag Site

Axplora, a global leader in API small molecule manufacturing, announced a significant investment at its Vizag site in India to expand production capacity and reinforce supply chain resilience. This announcement follows the successful completion of routine USFDA inspections in 2025 at both of Axplora’s Indian manufacturing sites, Vizag and Chennai, which form part of the company’s PharmaZell Business Unit. 

Combined, these milestones underscore Axplora’s long-term commitment to India as a strategic pillar of its global operations and its dedication to maintaining world-class quality and compliance standards.

The expansion project at Vizag will increase output and create new employment opportunities, enhancing Axplora’s ability to meet growing global demand for high-value pharmaceutical ingredients. The investment also advances the company’s sustainability goals by supporting efficient, vertically integrated production at a single site.

The Vizag and Chennai sites completed routine inspections by the US Food and Drug Administration (USFDA) in 2025, each concluding with a Voluntary Action Indicated (VAI) classification. 

The inspector at the Chennai facility highlighted the strong and consistent implementation of current Good Manufacturing Practices (cGMP), streamlined and efficient document management and retrieval processes, and the standards maintained in facility upkeep and overall site hygiene.

With enhanced capacity at Vizag and regulatory excellence demonstrated across both sites, Axplora continues to solidify its presence in India and its role as a trusted partner for the global pharmaceutical industry.